Adults with a body mass index of 25 to 26.9 do not qualify for GLP-1 weight-loss drugs, but about half of them may carry heart risk similar to people who do, according to research presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Milan.
The analysis, led by Karen Hvid of Copenhagen University Hospital in Herlev, Denmark, followed more than 313,000 adults with overweight or obesity in the UK and Denmark. People in the 25 to 26.9 BMI range who also had high remnant cholesterol, low-grade inflammation, or both had heart disease risk comparable to that of people eligible for semaglutide or tirzepatide.
